… patients with heartfailure and a left ventricularejectionfraction of more than 40% to receive dapagliflozin (… The primary outcome was a composite of worsening heartfailure (which was …
FA Martinez, M Serenelli, JC Nicolau, MC Petrie… - Circulation, 2020 - Am Heart Assoc
… of mortality and heartfailure hospitalization and improved symptoms in patients with heart failure and reduced ejectionfraction. We examined the effects of dapagliflozin according to …
… patients with heartfailure and reduced ejectionfraction (HFrEF) have chronic kidney disease … We assessed the safety and efficacy of dapagliflozin in patients with HFrEF, according to …
… in risk of cardiovascular death or worsening heartfailure when dapagliflozin was initiated in patients with heartfailure with reduced ejectionfraction, with particularly large absolute risk …
ME Nassif, SL Windsor, BA Borlaug, DW Kitzman… - Nature medicine, 2021 - nature.com
… Patients with heartfailure and preserved ejectionfraction (HFpEF) have a high burden of … patients with HFpEF (NCT03030235), we evaluated whether the SGLT2 inhibitor dapagliflozin …
… and safety of dapagliflozin in patients with HFimpEF. We hypothesized that patients with HFimpEF would benefit from dapagliflozin to a similar extent as patients with LVEF consistently …
… in patients with heartfailure and reduced ejectionfraction. In this analysis, we examine the effects of dapagliflozin on a … , using the Kansas City Cardiomyopathy Questionnaire (KCCQ). …
SD Solomon, RA de Boer, D DeMets… - … of heart failure, 2021 - Wiley Online Library
… of DAPA-HF that data from both dapagliflozinheartfailure trials, DAPA-HF and DELIVER, will … meta-analysis to assess the effect of dapagliflozin across the full spectrum of heartfailure. …
HA Blair - American Journal of Cardiovascular Drugs, 2021 - Springer
… The cardiovascular (CV) benefits of dapagliflozin were first observed in the DECLARE-TIMI … of dapagliflozin in patients with symptomatic heartfailure with reduced ejectionfraction in the …